Federal Prisons Suspend Controversial Nicotine Pouch Deal After FDA Review
A senior Bureau of Prisons (BOP) official ordered all federal prisons to stop procuring mindSHFT nicotine pouches on Sept. 3, 2026, pending an FDA review of whether the flavored 6-milligram pouches are authorized.[1]
BOP said the suspension followed consultations with the Food and Drug Administration and that no adverse health effects from the pouches have been reported so far.[1] The pouches are not FDA-authorized for U.S. marketing and are not sold commercially.[1] A whistleblower told Attorney General Todd Blanche and the Justice Department inspector general that distributing an improperly authorized nicotine product could pose serious health risks.[1]
On May 15, 2026, the BOP issued a request for information seeking FDA-authorized nicotine pouches.[1] SHFT Enterprise Holdings LLC was incorporated in Florida one week later.[1] A July 21 memo named SHFT as the sole approved vendor, and a July 29 memo recommended stocking three tins per inmate at facilities that carry the product.[1]
BOP agreed to pay $6.99 per tin and planned to charge inmates $9.10.[1] The program would have reached 118 institutions and more than 153,000 people in federal custody.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On September 3, 2026, a senior BOP official ordered all federal prisons to cease procuring mindSHFT nicotine pouches pending review.
- The mindSHFT 6-mg flavored nicotine pouches being sold in federal prisons are not FDA-authorized for U.S. marketing and are not sold commercially.
- Supplier SHFT Enterprise Holdings LLC was incorporated in Florida one week after BOP issued a May 15, 2026 request for information on FDA-authorized nicotine pouches.
- A July 21, 2026 BOP memo named SHFT as the sole approved vendor, and a July 29 memo recommended ordering three tins per inmate across the system.
- BOP pays $6.99 per tin and charges inmates $9.10, with more than 153,000 inmates in federal custody and 118 institutions allowed to stock the product.
- A whistleblower complaint to AG Todd Blanche and DOJ IG Don Berthiaume warned that distributing an improperly authorized nicotine product could pose serious health consequences.
- BOP says the suspension followed consultations with the FDA and that no adverse health effects from the pouches have been reported so far.
📰 Source Timeline (1)
Follow how coverage of this story developed over time